Cytokinetics

Cytokinetics reported a loss of $1.50 per share for Q2 2026 on revenue of $28.6 million, well above the consensus estimate of $17.09 million. The driver was the launch of the heart drug MYQORZO, which generated net product revenues of $25.3 million and treated more than 1,500 patients by the end of the quarter. The company raised its 2026 spending expectations due to increased commercial investments and holds $1.7 billion in cash. Management emphasized continued market momentum but noted risks from high costs, reliance on MYQORZO and reimbursement uncertainties. » Altro su de.investing.com

The MHRA has approved Cytokinetics’ Aficamten (MYQORZO) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. NICE recommends use in England and Wales for patients in NYHA classes II–III as an add‑on to optimized standard therapy or as monotherapy when there are contraindications. The decision is based on the phase‑3 SEQUOIA‑HCM study, which showed a mean difference in peak oxygen uptake of 1.7 ml/kg/min (p < 0.001) versus placebo. Common adverse events included hypertension, palpitations, dizziness and systolic dysfunction; availability through the NHS is expected later this year. » Altro su de.investing.com

Cytokinetics is transitioning from development to commercial stage following regulatory approvals for Myqorzo in the US, Europe and China, with early physician adoption and patient response supporting initial sales momentum. Positive trial readouts are expanding the drug's potential into related cardiac indications, while a differentiated mechanism and a pipeline of next-generation candidates could broaden its addressable market. Market interest and volume-supported price action indicate accumulation as investors reassess long-term growth and pricing power in a market with limited competition. » Altro su finance.yahoo.com